GenScript enables new workflows for CRISPR HDR cell therapy development

CRISPR-based non-viral gene insertion methods have gained popularity among research teams with concerns about the FDA’s recent draft guidance concerning the use of viruses for gene and cell therapy.

Non-viral HDR templates, in combination with CRISPR technology, can accelerate cell engineering compared to traditional GMP virus-based engineering, delivering results faster than alternate techniques.

One powerful application of CRISPR/Cas genome-editing technology involves the precise insertion of DNA sequences via the homology-directed repair (HDR) pathway.

Today, GenScript announced the availability of new GMP-grade GenExact™ single-stranded DNA (ssDNA) and GenWand™ closed-end linear double-stranded DNA (dsDNA) services. These services will enable next-generation gene and cell therapy R&D programs to advance to IND filing and clinical trials faster and more efficiently.

The announcement, which was made at the American Society of Gene & Cell Therapy (ASGCT) 25th annual meeting, further establishes GenScript as the leading provider of non-viral homology-directed repair (HDR) template solutions for immune-cell engineering.

GenScript now offers varying grades of non-viral HDR payload materials that support use cases across early discovery research, process development, and clinical studies.

ZingPR secured media coverage for the announcement in key trade publications